Cyclo Therapeutics, Inc.
NASDAQ: CYTH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- N. Scott Fine
- Employees
- 8
- Headquarters
- Gainesville, United States
- IPO year
- 2000
- Market cap
- $23.6M
- Website
- https://www.cyclotherapeutics.com
Loading CYTH…
Loading profile data…Frequently asked questions about CYTH
What does Cyclo Therapeutics, Inc. (CYTH) do?
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is...
Where does CYTH trade?
Cyclo Therapeutics, Inc. (CYTH) trades on the NASDAQ Capital Market.
What sector is CYTH in?
Cyclo Therapeutics, Inc. (CYTH) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Cyclo Therapeutics, Inc.?
N. Scott Fine is the chief executive officer of Cyclo Therapeutics, Inc. (CYTH).
Where is Cyclo Therapeutics, Inc. headquartered?
Cyclo Therapeutics, Inc. is headquartered in United States.
Does CYTH pay a dividend?
Cyclo Therapeutics, Inc. (CYTH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYTH go public?
Cyclo Therapeutics, Inc. (CYTH) completed its initial public offering in 2000.